10.17037/DATA.00003761
This dataset comprises individual-level data from participants in the POPVAC series of three randomised controlled trials. POPVAC A was conducted among schoolchildren from Koome islands, Uganda (a schistosomiasis-endemic setting), POPVAC B was conducted among schoolchildren from Jinja district, Uganda (a malaria-endemic setting), POPVAC C was conducted among schoolchildren from Entebbe, Uganda (a lower infection prevalence setting).
To access the data, requests must be made to the PI (Professor Alison Elliott). The request will be reviewed by the PI together with the POPVAC investigator team, in consultation with the POPVAC steering committee. The request will be reviewed based on scientific value and to ensure there is no overlap with existing work. If the request is approved, before data is shared, ethics approval will need to be obtained in your host institution and a Data Transfer Agreement with the MRC/UVRI and LSHTM Uganda Research Unit must be completed.
The following variables are contained within the POPVAC settings dataset.
Variable name | Variable description | Answer label | Answer code | Variable type |
study | POPVAC trial indicator | String | ||
Trial A | Trial A | |||
Trial B | Trial B | |||
Trial C | Trial C | |||
sex | Participant's sex | String | ||
Female | Female | |||
Male | Male | |||
age | Participant's age in years (age placed in categories where fewer participants) | Numeric | ||
Age 9 | 9 | |||
Age 10 | 10 | |||
Age 11 | 11 | |||
Age 12 | 12 | |||
Age 13 | 13 | |||
Age 14 | 14 | |||
Age 15 | 15 | |||
Age 16-17 | 16-17 | |||
bcg_w0 | BCG vaccine administered at week 0 | String | ||
Yes | 1 | |||
No | 0 | |||
Missing | . | |||
yf_w4 | Yellow fever vaccine administered at week 4 | String | ||
Yes | 1 | |||
No | 0 | |||
Missing | . | |||
hpv_w4 | HPV vaccine administered at week 4 | String | ||
Yes | 1 | |||
No | 0 | |||
Missing | . | |||
hpv_w8 | HPV vaccine administered at week 8 | String | ||
Yes | 1 | |||
No | 0 | |||
Missing | . | |||
hpv_w28 | HPV vaccine administered at week 28 | String | ||
Yes | 1 | |||
No | 0 | |||
Missing | . | |||
atleastone_ot_dose | At least one dose of oral typhoid administered at week 4 | String | ||
Yes | 1 | |||
No | 0 | |||
Missing | . | |||
td_w28 | Tetanus-diphtheria administered at week 28 | String | ||
Yes | 1 | |||
No | 0 | |||
Missing | . | |||
tt_igg_baseline | Tetanus toxoid-specific IgG at trial "baseline" (baseline for Td), IU/ml | Continuous | Numeric | |
tt_igg_week52 | Tetanus toxoid-specific IgG at week 52, IU/ml | Continuous | Numeric | |
dt_igg_baseline | Diphtheria toxoid-specific IgG at trial "baseline" (baseline for Td), IU/ml | Continuous | Numeric | |
dt_igg_week52 | Diphtheria toxoid-specific IgG at week 52, IU/ml | Continuous | Numeric | |
bcg_ifng_baseline | IFN-gamma response to BCG at baseline0 (SFUs per million PBMCs) | Continuous | Numeric | |
bcg_ifng_week8 | IFN-gamma response to BCG at week 8 (SFUs per million PBMCs) | Continuous | Numeric | |
bcg_ifng_week52 | IFN-gamma response to BCG at week 52 (SFUs per million PBMCs) | Continuous | Numeric | |
yf_50_week0 | Yellow fever PRNT 50 titre at week 0 | Continuous | Numeric | |
yf_50_week8 | Yellow fever PRNT 50 titre at week 8 | Continuous | Numeric | |
yf_50_week52 | Yellow fever PRNT 50 titre at week 52 | Continuous | Numeric | |
yf_90_week0 | Yellow fever PRNT 90 titre at week 0 | Continuous | Numeric | |
yf_90_week8 | Yellow fever PRNT 90 titre at week 8 | Continuous | Numeric | |
yf_90_week52 | Yellow fever PRNT 90 titre at week 52 | Continuous | Numeric | |
typhi_igg_week0 | S. typhi O:LPS-specific IgG at week 0, EU/ml | Continuous | Numeric | |
typhi_igg_week8 | S. typhi O:LPS-specific IgG at week 8, EU/ml | Continuous | Numeric | |
typhi_igg_week52 | S. typhi O:LPS-specific IgG at week 52, EU/ml | Continuous | Numeric | |
hpv16_wk0 | HPV-16-specific IgG concentration at week 0, EU/ml | Continuous | Numeric | |
hpv16_wk8 | HPV-16-specific IgG concentration at week 8, EU/ml | Continuous | Numeric | |
hpv16_wk52 | HPV-16-specific IgG concentration at week 52, EU/ml | Continuous | Numeric | |
hpv18_wk0 | HPV-18-specific IgG concentration at week 0, EU/ml | Continuous | Numeric | |
hpv18_wk8 | HPV-18-specific IgG concentration at week 8, EU/ml | Continuous | Numeric | |
hpv18_wk52 | HPV-18-specific IgG concentration at week 52, EU/ml | Continuous | Numeric | |
caa_result_baseline_num | S. mansoni CAA result at baseline | String | ||
Positive | Positive | |||
Negative | Negative | |||
sea_ug_ml | Schistosoma egg antigen-specific IgG, ug/ml | Continuous | Numeric | |
pfal_res_baseline_num | Malaria status at baseline, PCR | String | ||
Positive | Positive | |||
Negative | Negative | |||
PfMSP2_IgG_titre | PfMSP2 IgG titre at baseline | Continuous | Numeric | |
PfAMA1_IgG_titre | PfAMA1 IgG titre at baseline | Continuous | Numeric | |
bmi | Body mass index | Continuous | Numeric | |
treated_worm_12m | Treated for worms in the last 12 months (reported at enrolment) | String | ||
Yes | Yes | |||
No | No | |||
Missing | . | |||
treated_malaria_12m | Treated for malaria in the last 12 months (reported at enrolment) | String | ||
Yes | Yes | |||
No | No | |||
Missing | . | |||
resid_b | Residence at birth | String | ||
Village | Village | |||
Town/city | Town/city | |||
Missing | . | |||
resid_5y | Residence between birth and 5 years | String | ||
Village | Village | |||
Town/city | Town/city | |||
Missing | . | |||
sm_screening_caa_pcr | S. mansoni positive on either CAA or PCR at baseline | String | ||
Positive on at least one of CAA or PCR | 1 | |||
Negative on both CAA and PCR | 0 | |||
sm_screening_pcr | S. mansoni PCR result at baseline | Positive, Negative | String | |
Positive | pos | |||
Negative | neg | |||
necator_pcr_screening | Necator americanus PCR result baseline | String | ||
Positive | Pos | |||
Negative | Neg | |||
Missing | . | |||
strongyloides_pcr_screening | Strongyloides stercoralis PCR result at baseline | String | ||
Positive | Pos | |||
Negative | Neg | |||
Missing | . |